Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard Mega Cap Growth ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Vanguard Mega Cap Growth ETF trades at $88.95. The key difference: Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | MGK | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $92.06 |
52-Week Low | $0.53 | $70.70 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
MGK (Vanguard Mega Cap Growth ETF) trades at $87.69, down 1.54% today amid a bearish technical signal. The ETF maintains a concentrated portfolio of 69 large-cap growth stocks with heavy technology exposure and a low 0.05% expense ratio. Recent developments include a 1:5 stock split effective April 21, 2026, and potential addition of SpaceX following its recent IPO.
The ETF's concentrated mega-cap growth strategy offers strong long-term return potential but carries sector concentration risk. Technical indicators suggest near-term consolidation while fundamental strength in technology holdings supports the bullish long-term thesis. Investors should weigh the ETF's historical outperformance against its vulnerability to tech sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
